194 related articles for article (PubMed ID: 34240274)
21. The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma.
Sun B; Chen H; Lao J; Tan C; Zhang Y; Shao Z; Xu D
J Pathol Clin Res; 2023 Sep; 9(5):409-422. PubMed ID: 37395342
[TBL] [Abstract][Full Text] [Related]
22. Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer.
Al Amri WS; Allinson LM; Baxter DE; Bell SM; Hanby AM; Jones SJ; Shaaban AM; Stead LF; Verghese ET; Hughes TA
Mol Cancer Ther; 2020 Mar; 19(3):945-955. PubMed ID: 31879365
[TBL] [Abstract][Full Text] [Related]
23. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
24. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
[TBL] [Abstract][Full Text] [Related]
25. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
26. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
[TBL] [Abstract][Full Text] [Related]
27. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
28. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
Zhang X; Su X; Guo Z; Jiang X; Li X
J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
[TBL] [Abstract][Full Text] [Related]
29. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.
Liu L; Kimball S; Liu H; Holowatyj A; Yang ZQ
Oncotarget; 2015 Feb; 6(4):2466-82. PubMed ID: 25537518
[TBL] [Abstract][Full Text] [Related]
30. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
31. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
32. SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.
Hassan N; Rutsch N; Győrffy B; Espinoza-Sánchez NA; Götte M
Sci Rep; 2020 Feb; 10(1):2262. PubMed ID: 32042016
[TBL] [Abstract][Full Text] [Related]
33. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
34. Genomic characterization of metastatic breast cancers.
Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
[TBL] [Abstract][Full Text] [Related]
35. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
[No Abstract] [Full Text] [Related]
36. Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer.
Wu J; Zhang Y; Li M
J Comput Biol; 2019 Dec; 26(12):1394-1408. PubMed ID: 31290690
[TBL] [Abstract][Full Text] [Related]
37. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
Kayser S; Feszler M; Krzykalla J; Schick M; Kramer M; Benner A; Thol F; Platzbecker U; Müller-Tidow C; Ho AD; Ehninger G; Heuser M; Schlenk RF; Thiede C; Röllig C; Krämer A
Eur J Haematol; 2017 Dec; 99(6):544-552. PubMed ID: 28940816
[TBL] [Abstract][Full Text] [Related]
39. Prognosis model of colorectal cancer patients based on
Liu K; Wang JF; Zhan Y; Kong DL; Wang C
J Gastrointest Oncol; 2021 Feb; 12(1):79-88. PubMed ID: 33708426
[TBL] [Abstract][Full Text] [Related]
40. Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer.
Li X
BMC Cancer; 2017 Apr; 17(1):252. PubMed ID: 28390392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
